top of page

PBH Health LLC does not promote compounded medications as equivalent to or substitutes for FDA-approved drugs. All treatment decisions are made by licensed providers based on individual patient needs. 

​​​​

GLP-1 Updates & Regulatory Compliance

Our Commitment to Safe, Accurate, and Compliant Care

​

PBH Health LLC is committed to providing patients with accurate, transparent, and medically appropriate information regarding GLP-1 therapies. We actively monitor regulatory guidance and align our clinical and communication practices with current standards established by the U.S. Food and Drug Administration (FDA).

​

Important Update on Compounded GLP-1 Medications (February 2026)

In February 2026, the FDA issued guidance regarding non-FDA-approved GLP-1 medications, including compounded products. In accordance with this guidance, PBH Health LLC maintains the following standards:

  • Compounded GLP-1 medications are not FDA-approved

  • Compounded medications are not represented as equivalent to or substitutes for FDA-approved drugs

  • PBH Health LLC does not describe compounded medications as “generic” versions of FDA-approved products

  • PBH Health LLC does not claim that compounded medications produce the same clinical outcomes as FDA-approved medications

 

How PBH Health LLC Ensures Compliance

To ensure ongoing compliance and patient safety, PBH Health LLC has implemented the following safeguards:

Clinical Oversight

  • All treatment decisions are made by licensed healthcare providers based on individualized medical evaluation

  • Prescriptions are issued only when medically appropriate and supported by clinical criteria

Clear Patient Communication

  • Patients are informed when a medication is FDA-approved versus compounded

  • All communications avoid misleading or comparative claims

Standardized Medical Documentation

  • Providers use structured documentation that includes required disclosures regarding compounded medications

  • Compliance language is standardized and consistently applied

Content Review and Monitoring

  • Website and patient-facing materials are regularly reviewed for regulatory compliance

  • Updates are made promptly in response to new FDA guidance

 

Patient-Centered Treatment Approach

GLP-1 therapies may be considered as part of a broader, individualized care plan that includes:

  • Nutrition and lifestyle modification

  • Ongoing clinical monitoring

  • Risk-benefit evaluation specific to each patient

  • ​

PBH Health LLC does not guarantee outcomes and does not promote any medication as universally appropriate. Treatment recommendations are based solely on clinical judgment and patient-specific needs.

​

Transparency and Accountability

PBH Health LLC maintains a conservative, compliance-first approach to healthcare communication. Our goal is to ensure that all information provided to patients is:

  • Accurate

  • Non-misleading

  • Appropriately qualified

  • Consistent with current regulatory guidance

  • ​

Questions

If you have questions about GLP-1 therapies or your treatment plan, please contact:

PBH Health LLC


Dr Pamela Herbert, Medical Director

1111 Pennsylvania Ave SE, Ste 204

Washington DC, 20003

drherbert@pbhhealthllc.com

Phone:202-455-0638

Fax: 202-449-1044

​

​

​

​

​

bottom of page